Search company, investor...
Canary Foundation company logo

Canary Foundation

Founded Year


About Canary Foundation

Canary Foundation was founded in 2004 by Don Listwin, a successful high-technology executive who lost his mother to misdiagnosed ovarian cancer. Don discovered that although almost $10 billion is spent annually on cancer research in the United States, the vast majority is allocated to developing new cancer treatments and caring for patients. Surprisingly, little funding is available to researchers investigating new ways to detect cancer it at its earliest, curable stages. Don made a commitment to use his time, energy, expertise, enthusiasm, professional network, and his own family foundation's resources to build a non-profit organization that will succeed at the creation of an early warning system for cancer. His ongoing passion is to build the foundation that connects the very best cancer researchers with entrepreneurs and venture capitalists so that their breakthroughs will have chances of saving lives. Don recruited Dr.Lee Hartwell, 2001 Nobel Laureate, to help form the Canary Science Team from the most outstanding, scientifically researchers available from various disciplines. Science team members come from widely different fields and institutions to meet on a regular basis where they share ideas and breakthroughs. Canary has devised a simple process to provide money and tools for team members to accomplish their stated goals at a rapid pace and with directly applicable results. Tools include software to share data, dedicated websites, project management support, quarterly collaboration meetings and project reviews. One of a decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers produced by cancer. Ovarian cancer was chosen as it is generally considered asymptomatic until late stage and has relatively low occurrence. Knowledge, techniques, and data gathered from the Ovarian Cancer Program are being leveraged to expand into other types of cancers (Pancreatic, Prostate and Lung). In addition to blood tests, the Science Team is working on advancing imaging techniques and agents for general body scanning technology using PET, Ultrasound and other imaging modalities for pinpointing the exact cancer location in order to eradicate it while it is still small and before it has spread. Canary hopes that by delivering on a effective test for early detection of cancer it will spur a dramatic increase of funds into the early detection field from the National Cancer Institute and the venture capital community so that products based on this research will arrive faster and save millions of lives per year.

Headquarters Location

333 West Santa Clara Street

San Jose, California, 95113,

United States


Missing: Canary Foundation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Canary Foundation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Canary Foundation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Canary Foundation is included in 2 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Latest Canary Foundation News

Cancer Biomarkers’ Editor-in-Chief Sudhir Srivastava wins prestigious Don Listwin Award

Nov 1, 2022

Amsterdam, November 1, 2022 – The journal Cancer Biomarkers (CBM) and publisher IOS Press are pleased to share the news that CBM’s Editor-in-Chief Sudhir Srivastava, PhD, MPH, has been awarded the 2022 Don Listwin Award for Outstanding Contribution to Cancer Early Detection. This award recognizes a sustained contribution to, or singular achievement in, the cancer early detection field. The award is named in honor of Don Listwin, founder and chairman of Canary Foundation. Credit: Sudhir Srivastava, PhD, MPH Amsterdam, November 1, 2022 – The journal Cancer Biomarkers (CBM) and publisher IOS Press are pleased to share the news that CBM’s Editor-in-Chief Sudhir Srivastava, PhD, MPH, has been awarded the 2022 Don Listwin Award for Outstanding Contribution to Cancer Early Detection. This award recognizes a sustained contribution to, or singular achievement in, the cancer early detection field. The award is named in honor of Don Listwin, founder and chairman of Canary Foundation. Dr. Srivastava received the award at the 5th Annual Early Detection of Cancer Conference held last month in recognition of his numerous contributions to cancer early detection, particularly biomarker-based diagnostics. He commented, “The field of biomarkers in cancer detection has come a long way. There was a time when research on biomarker discovery and development was a topic for academics and government; now it has attracted private sectors and philanthropic institutions to actively support the cause of early detection. Nothing can be more gratifying than to witness such a remarkable progress and evolution in biomarker-based diagnostics that is likely to revolutionize personalized, precision early detection, prevention and treatment of cancer. I am humbled to receive this prestigious award and fortunate to be surrounded by dedicated investigators, colleagues and patient advocates for their dedication and motivation toward cancer early detection.” Dr. Srivastava is Senior Scientific Officer and Chief of the Cancer Biomarkers Research Branch in the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH). His achievements include having established a number of transformative programs on translational research on cancer screening, early detection, risk assessment and enabling technologies including artificial intelligence with a network of leading experts in medicine, science, computational biology that has advanced scientific discoveries and revolutionized diagnostics in cancer early detection. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network, a flagship program at the NCI that has begun translating biomarkers into clinical tests (> 8 FDA approved and > 19 CLIA certified) for early detection. This network has been a pioneer in applying innovative technologies in the validation of cancer biomarkers as well as in the development of a national informatics infrastructure to support the research. In recognition of his leadership in cancer diagnostics, Dr. Srivastava was featured in Wired magazine in August 2003, and more recently, has been awarded a Distinguished Public Service Award (2016) by the American Pancreatology Association, a Distinguished Clinical and Translational Proteomics Award (2017) by HUPO International, and the Distinguished NCI Cancer Prevention Fellowship Program (CPFP) Alumni Award (2016). “We would like to congratulate Dr. Srivastava on winning this prestigious award that acknowledges his many significant contributions to the advancement of early cancer detection research. We are extremely proud of our partnership with him on Cancer Biomarkers, which publishes validated content for the global cancer early detection community, dedicated to reducing suffering and death due to cancer,” said Gabriela Ricci, Associate Publisher, IOS Press.

Canary Foundation Frequently Asked Questions (FAQ)

  • When was Canary Foundation founded?

    Canary Foundation was founded in 2004.

  • Where is Canary Foundation's headquarters?

    Canary Foundation's headquarters is located at 333 West Santa Clara Street, San Jose.

  • Who are Canary Foundation's competitors?

    Competitors of Canary Foundation include BioDtech, Linkage Biosciences, AdvanDx, Nodality, Hematotypes and 12 more.

Compare Canary Foundation to Competitors


Litholink offers metabolic evaluations for kidney stone formers.

Xeptagen S.p.A.

XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.


StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.


Hematotypes is a medical technology company dedicated to improving the way cancers of the blood, lymphoma, and leukemia are identified.

Flex Biomedical

Flex Biomedical is developing technologies to treat and diagnose orthopedic diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer, designed to treat osteoarthritis.

Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.